Company news

Share this article:

GlaxoSmithKline has inked a deal worth as much as $425 million to develop drugs for respiratory and cardiovascular disease with San Diego company Amira Pharmaceuticals. The deal will give GSK worldwide rights to develop, manufacture and sell experimental compounds including an experimental asthma treatment known as AM103, which has already has shown promise in early human trials. Amira could receive as much as $425 million in payments if it meets all of its development and regulatory milestones. It also will receive royalty payments on sales of any of its drugs.

Roska Healthcare Advertising has launched a new Web site at www.roskahealthcare.com offering visitors a virtual tour of the firm's people, clients and category experience.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.